Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib vs placebo in advanced hepatocellular carcinoma after prior anti-angiogenic therapy failure
CTR20132977Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of axitinib in hepatocellular carcinoma (HCC), sponsored by Pfizer. Started Apr 2015; status: completed.
02
Drugs
axitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20132977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132977.